CA2265885A1 - Therapie a but immunitaire - Google Patents

Therapie a but immunitaire Download PDF

Info

Publication number
CA2265885A1
CA2265885A1 CA002265885A CA2265885A CA2265885A1 CA 2265885 A1 CA2265885 A1 CA 2265885A1 CA 002265885 A CA002265885 A CA 002265885A CA 2265885 A CA2265885 A CA 2265885A CA 2265885 A1 CA2265885 A1 CA 2265885A1
Authority
CA
Canada
Prior art keywords
amino acid
glu
asp
sequence
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002265885A
Other languages
English (en)
Inventor
Patrick T. Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2265885A1 publication Critical patent/CA2265885A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

L'invention concerne une séquence d'acides aminés présentant des groupes de paires d'ions spécifiques (ponts) ceints au moins d'un côté par des segments transmembranaires hydrophobes non polaires, en tant que mécanisme utilisé par de nombreux agents infectieux et plusieurs facteurs d'inhibition de la cytokine, tels que l'interleukine 10, le facteur d'inhibition de la prolactine et l'alpha-foeto-protéine. Ladite séquence n'est pas seulement utilisée pour amoindrir les défenses immunitaires des hôtes mais également pour permettre l'infection de tissus lymphoïdes cibles. Il a été prouvé que certains vaccins, lorsqu'ils sont inoculés à un hôte, produisent un certaine gamme d'anticorps neutralisants mais n'empêchent pas l'infection lorsque cet hôte est ensuite exposé à un organisme infectieux vivant. Dans la thérapie de l'invention, lorsque l'inoculation de ce type de vaccin est combinée à une immunisation passive au moyen d'anticorps mono ou polyclonaux dirigés contre lesdites séquences d'acides aminés, l'hôte est capable de surmonter l'agression infectieuse. L'invention se rapporte à l'utilisation thérapeutique d'anticorps mono ou polyclonaux dirigés contre lesdites séquences spécifiques, comme traitement du syndrome d'immunodéficience acquise (SIDA) et d'autres états pathologiques qui persistent en raison de la présence d'un facteur d'inhibition de la cytokine d'origine virale, bactérienne ou provenant de l'hôte, tel que le syndrome de fatigue chronique dans lequel les molécules d'imitation de l'interleukine 10 sont responsables d'une multitudes de symptômes identifiés comme indicateurs de l'encéphalomyélite. L'invention se rapporte à l'utilisation thérapeutique d'anticorps mono ou polyclonaux dirigés contre ces séquences d'acides aminés spécifiques, sous forme de thérapie associée au moyen de vaccins et d'agents antiviraux pour la prévention des effets secondaires de certains agents de modulation des défenses immunitaires et antiviraux (ex: DHEA et IL-12) qui provoquent la production accrue de molécules d'imitation de l'interleukine 10 ou de l'alpha-foetoprotéine pendant la thérapie. L'invention se rapporte encore à l'utilisation thérapeutique de ces séquences spécifiques, soit isolées de la source de l'organisme source, soit produites par synthèse directe ou synthèse de protéines recombinaison. Ces peptides, lorsqu'ils sont administrés à un patient souffrant d'une maladie auto-immune, tels que, entre autres, la sclérose en plaques, le lupus érythémateux (lupus érythémateux systémique), le diabète ou la polyarthrite rhumatoïde ou à des receveurs de transplant, permettent de modifier l'état immunitaire du patient de sorte que soit produite une réponse immunitaire dépendante de l'anticorps Th¿2? et que soit inhibée l'attaque immunitaire de Th¿1? (dépendant des lymphocytes) qui se manifeste dans ces types de déficiences immunitaires, telles que la sclérose en plaques et la réaction du greffon contre l'hôte. Certaines affections dermatologiques qui sont aujourd'hui traitées au moyen de crèmes et d'onguents corticostéroïdes peuvent être également traitées avec succès par le remplacement des corticostéroïdes par ces séquences immunosuppressives d'imitation de l'interleukine 10 et de l'alpha-foet?E?otéine de l'invention.
CA002265885A 1996-09-11 1997-09-10 Therapie a but immunitaire Abandoned CA2265885A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2518096P 1996-09-11 1996-09-11
US60/025,180 1996-09-11
PCT/IB1997/001086 WO1998010787A2 (fr) 1996-09-11 1997-09-10 Therapie a but immunitaire

Publications (1)

Publication Number Publication Date
CA2265885A1 true CA2265885A1 (fr) 1998-03-19

Family

ID=21824510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265885A Abandoned CA2265885A1 (fr) 1996-09-11 1997-09-10 Therapie a but immunitaire

Country Status (9)

Country Link
EP (1) EP0929568A2 (fr)
JP (1) JP2001503613A (fr)
CN (1) CN1230195A (fr)
AU (2) AU6887096A (fr)
CA (1) CA2265885A1 (fr)
IL (1) IL128806A0 (fr)
NZ (1) NZ335039A (fr)
SE (1) SE9900812L (fr)
WO (2) WO1998010792A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5297299A (en) * 1998-08-17 2000-03-06 Patrick T. Prendergast Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
WO2000035472A2 (fr) * 1998-12-15 2000-06-22 Hollis-Eden Pharmaceuticals, Inc. Cytokinotherapie combinee
EP1265634A4 (fr) * 2000-03-14 2005-12-28 Nat Jewish Med & Res Center Procede et composition pour traiter une hyperreactivite bronchique
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
WO2005116081A2 (fr) 2004-05-24 2005-12-08 Genvault Corporation Stockage proteique stable et stockage d'acides nucleiques stable sous forme recuperable
EA008925B1 (ru) * 2004-12-14 2007-08-31 Товарищество С Ограниченной Ответственностью "Реал Мед Компани" Способ коррекции иммунного состояния организма при сахарном диабете
US7989590B2 (en) * 2005-03-22 2011-08-02 Rohto Pharmaceutical Co., Ltd Peptides that increase collagen or hyaluronic acid production
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
CN114163493B (zh) * 2021-11-18 2023-09-15 浙大宁波理工学院 一种可作为5型磷酸二酯酶抑制剂的多肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056249B1 (fr) * 1981-01-09 1985-06-26 New York Blood Center, Inc. Composition synthétique d'antigènes et leur procédé de préparation
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
AU1366088A (en) * 1987-01-28 1988-08-24 Ortho Pharmaceutical Corporation Immunosuppressive peptides and methods of use
AU620804B2 (en) * 1987-03-23 1992-02-27 Hiver Limited Novel vaccines
SE8705197D0 (sv) * 1987-12-30 1987-12-30 Jonas Blomberg New peptides, two diagnostic methods using the peptides and a medicament based on the peptides
IL97629A0 (en) * 1990-03-26 1992-06-21 Schering Corp Bcrf1 antagonists for treating epstein-barr virus infections
WO1993011157A1 (fr) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX)
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
WO1993018783A1 (fr) * 1992-03-20 1993-09-30 Schering Corporation Utilisation d'interleukine 10 pour induire la production d'antagoniste des recepteurs de l'interleukine 1
CA2144648A1 (fr) * 1992-09-18 1994-03-31 Mario Clerici Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih
NZ269766A (en) * 1993-07-28 1998-01-26 Medvet Science Pty Ltd Haemopoietic growth factor antagonists; relates to modified forms of such factors
DE69536065D1 (de) * 1994-01-14 2010-05-27 Rath Matthias Hydrophile Signal-Oligopeptide und Verfahren der therapeutischen Anwendung
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues

Also Published As

Publication number Publication date
EP0929568A2 (fr) 1999-07-21
AU4132097A (en) 1998-04-02
NZ335039A (en) 2001-04-27
SE9900812D0 (sv) 1999-03-08
WO1998010787A3 (fr) 1998-07-30
CN1230195A (zh) 1999-09-29
JP2001503613A (ja) 2001-03-21
AU6887096A (en) 1998-04-02
IL128806A0 (en) 2000-01-31
WO1998010792A1 (fr) 1998-03-19
WO1998010787A2 (fr) 1998-03-19
SE9900812L (sv) 1999-03-08

Similar Documents

Publication Publication Date Title
EP0529023B1 (fr) Peptides et fragments de peptides efficaces therapeutiquement
CA2158455C (fr) Chimeres immunogenes comportant des sequences d'acides nucleiques codant pour les peptides de la sequence du signal du reticule endoplasmique et au moins un autre peptide, et leurs ustilisations dans les vaccins et le traitement des maladies
Fallarino et al. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo
KR100235849B1 (ko) HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
US7109026B2 (en) Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
CA2265885A1 (fr) Therapie a but immunitaire
KR20190126798A (ko) 당뇨병 치료를 위한 펩티드 및 방법
Cruikshank et al. Signaling and functional properties of interleukin-16
JPH07110877B2 (ja) Ｈｉｖ逆転写酵素に対する細胞毒性ｔ細胞免疫を刺激するペプチド
US5820865A (en) Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
AU660422B2 (en) Pathogen-specific CTL therapy
EP0719281B1 (fr) Constructions de peptides a branches multiples destines a etre utilises contre le vih
NZ243929A (en) Compositions of e.coli outermembrane proteins
EP0960886B1 (fr) Peptide T et peptides associes destines au traitement des inflammations, notamment la sclerose en plaques
US7521426B2 (en) HIV-specific CTL inducing peptides and medicaments for preventing or treating AIDS comprising the peptides
RU2126266C1 (ru) Способ ингибирования ретровирусной инфекции (варианты), ингибитор протеазы, кодирующая его нуклеиновая кислота и способ рекомбинантного продуцирования серинового ингибитора
ES2352745T3 (es) Cd86 de felino.
AU682256B2 (en) Pathogen-specific CTL therapy
Auffray et al. CD4-targeted immune intervention: a strategy for the therapy of AIDS and autoimmune disease
AU656414B2 (en) Immunostimulation
JP2002356498A (ja) 滑膜肉腫抗原ペプチド

Legal Events

Date Code Title Description
FZDE Discontinued